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Swedish National Diabetes Register (NDR) for 35,238 persons with type 2 diabetes
aged 30-74 years at diagnosis from January 1, 2004 to December 31, 2008 were
analyzed using the conditional non-frailty Weibull model. To not underestimate
the effect of BMI, two specifications of the model were estimated. Age at diagnosis,
sex, hypoglycaemic treatment, diabetes duration, microalbuminuria and smoking
were common covariates in both models.RESULTS:A total of 1409 patients had one
MI event and 200 experienced two events. The results showed that the risk of a
second MI differ from the risk of having a first MI. In addition, the effects of cova-
riates were not constant between multiple events. Women had a lower risk for
developing a first event compared to men, but a higher risk for a second event
conditional on the first MI. Preliminary results indicate four times higher hazard of
developing a MI conditional on a first MI during the follow up. CONCLUSIONS: The
findings show the need for an update of simulation models including health-eco-
nomic models and risk engines to include separate transition probabilities for first
and subsequent events for correct predictions of costs and quality of life gains.
Using recurrent event risk equations may reduce the bias from the previous as-
sumption of constant transition probabilities for consecutive events in health eco-
nomic models.
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OBJECTIVES: To assess the health and budget impact of increasing use of rosuvas-
tatin in patients with high cardiovascular risk, while maintaining the overall level
of use, upon the entry of generic atorvastatin in Sweden. METHODS: A model was
developed to estimate the budget impact associated with changed statin utilization
pattern in different risk groups. The Framingham Risk equation was used to esti-
mate cardiovascular events, and the relative risk reduction for statins was modeled
using the JUPITER (Justification for the Use of statins in Primary prevention: an
Intervention Trial Evaluating Rosuvastatin) trial. A similar relative risk reduction
was used for primary and secondary prevention settings based on available liter-
ature. Baseline risk distribution was derived from the Malmö Primary Prevention
Study. The use of rosuvastatin was assumed to increase from 4% (2011) to 7% (2014)
in the high-risk group (27% baseline 10-year Framingham risk), but the overall use
was kept unchanged (4%). A gradual atorvastatin use increase was assumed with a
corresponding decrease in simvastatin use over 3 years. Cost calculations were
from Swedish public health sources. Generic price for atorvastatin was assumed to
be 5% of branded price. RESULTS: For the Swedish population on statin treatment
(810,304 patients, 25% with a previous history of CVD) the estimated budget impact
decreased by SEK 359 millions in 2012 (compared with 2011) and by SEK 441 mil-
lions in 2014 with changed statin utilization. The estimated number of CVD events
avoided ranged from 98 in 2012 to 197 in 2014 compared with current year (0.81%
decrease over the 3-year period). CONCLUSIONS: A shift to generic atorvastatin in
2012, accompanied by increased use of rosuvastatin in high-risk patients whilst
maintaining rosuvastatin overall use at current levels, was estimated to prevent
more cardiovascular events and resulted in overall healthcare budget savings for
the 3-year period in Sweden.
PCV39
HEPARIN-INDUCED THROMBOCYTOPENIA TYPE II IN TIMES OF DEMOGRAPHIC
CHANGES – EPIDEMIOLOGICAL AND ECONOMIC ASPECTS IN GERMANY
Schopohl D, Berger K, Schramm W
University Hospital of Munich, Muenchen, Germany
OBJECTIVES: The antibody-mediated, prothrombotic heparin-induced thrombocy-
topenia type II (HIT-II) is a life-threatening disease with high thrombosis risk of
38-76% and up to 20% mortality. Pulmonary embolism occurs in up to 40% of pa-
tients, and amputations are necessary in up to 15%. The objective was to evaluate
frequency and cost of HIT-II in Germany. METHODS: Systematic literature
searches regarding epidemiology and cost of HIT-II were conducted until end of
2000 with Medical Subject Heading terms “incidence”, “epidemiology”, “risk”, and
“cost” each in combination with “heparin-induced thrombocytopenia”. German
secondary data were obtained by desktop research from the German Federal Sta-
tistical Office and a German university hospital. RESULTS: Literature search
yielded eleven relevant publications selected by successive title, abstract and
whole publication screening from a total of 1225 hits. Published incidence for HIT-II
in Germany was 0.039% for in-hospital patients, and average additional costs per
patient amounted to €9004 (Wilke et al., J Thromb Haemost, 2009). Data from the
German Federal Statistical Office for 2009 show an incidence of 0.05% for patients
with secondary diagnosis HIT-II, ICD-10 Code D69.53, corresponding to 8,585 cases
(age peak 65-85 years) with an average prolongation of hospital stay by 18 days. The
frequency of documented HIT-II as secondary diagnosis increased since 2005 by
60.4% (2005: 5353; 2006: 6263; 2007: 7177; 2008: 7454 cases). Estimated additional
costs generated by HIT-II in Germany in 2005 amount to 48 million euro, and in 2009
to a minimum of 77 million euro. CONCLUSIONS: Cost and burden of HIT-II are
considerable. Due to the demographic development to be expected in Germany
during the next decades in combination with the age peak of the disease a further
increase in HIT-II cases has to be anticipated. Data are limited. Further epidemio-
logical research and analysis of burden of disease from several perspectives are
needed.
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OBJECTIVES: To estimate the hospital impact with the introduction of vernakalant
in hospital emergency departments (EDs) in Spain.METHODS: Patients with recent
onset atrial fibrillation (AF) (48H) or non-permanent AF without thromboembolic
risk (anticoagulation or negative transesophageal echocardiography) were in-
cluded in the ED setting. Scenario: Data derived from the RHYTHM-AF-Spain study
or determined by the hospital. Budget impact model with the following variables:
percentage of use of anti-arrhythmic drugs (AAD) before and after the entry of
vernakalant, time to cardioversion with AAD and number of patients per year that
could be treated with vernakalant. Outcome variables: impact on pharmacy bud-
get, length of stay in ED (cost offset, additional patients treated in ED). Time to
achieve sinus rhythm for vernakalant, drug cost, and hospital stay were obtained
from published data. RESULTS: According to Spanish RHYTHM-AF study data, in
67% of these patients cardioversion (CV) is attempted with the following AAD (pro-
portion; mean time to normal sinus rhythm): amiodarone iv (55%; 7 hours), flecain-
ide iv/oral (12%/28%; 1.5/4.2 hours), propafenone iv/oral (1%/4%; 2/6.1 hours). It is
estimated that in a hospital like those enrolled in RHYTHM-AF, approximately 150
patients per year would be admitted into the ED and pharma-cardioversion would
be attempted in 101. Assuming that AADs were partially substituted for vernakal-
ant (30% for amiodarone, 15% flecainide oral, 5% flecainide iv, and 5% propafenone
oral), 22 patients would receive vernakalant per year. The annual incremental cost
is €7,772.13, but offset in 63.4% due to a reduction of 123.16 hours of stay in the ED
that would also allow for the assistance of 15 additional patients. CONCLUSIONS:
The reduction of hospital stay associated with the use of vernakalant carries a high
percentage of compensation costs associated with reduction of stay in the ED and
frees up resources to attend to more patients.
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OBJECTIVES: There has been enormous interest in the potential benefit, primarily
around decreased medical resource use, of the introduction of telehealth home
monitoring systems (THMS) for chronic disease management. Widespread adop-
tion has nevertheless been slow due to a lack of information on the financial im-
plications of implementation. THMS requires a substantial initial investment
which in a time of budget cuts needs economic justification. The objective of this
study was to provide an estimate of the potential short-term financial implications
of introducing the Care Innovations™ Guide THMS for patients with chronic heart
failure (CHF) in a typical PCT within the UK. METHODS: A one-year budget impact
model was developed looking at key financial drivers of CHF care including GP
visits, unplanned hospitalisation, ambulance time, etc. The model assessed the
impact on these costs after the introduction a THMS package for a PCT with a
population of 500,000, assuming the initial THMS uptake would be 30% of CHF
patients. Population and disease incidence and prevalence data for England were
taken from the Quality and Outcomes Framework 2009-10. Average costs per unit
of medical resource use, amount of resource use per year for a typical chronic CHF
patient receiving standard care and estimates of the impact of the THMS on re-
source use were estimated from published literature. RESULTS: The model esti-
mated that the introduction of THMS required an initial investment of £9,440,567
but yielded a return of 2% (£158,812) within one year. CONCLUSIONS: The intro-
duction of THMS requires considerable initial investment; however this model
suggests that this is offset within a very short time-frame due to reductions in
medical resource usage and is expected to lead to substantial savings over the
medium-term. This should encourage decision-makers to seriously consider mov-
ing from small pilot studies to more widespread implementation of THMS.
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OBJECTIVES:To assess the economic impact of adding SevikarHCT® to the Spanish
market for the treatment of arterial hypertension in the adult population aged over
35. SevikarHCT® concerns a new three-in-one combination tablet containing olm-
esartan medoxomil, amlodipine and hydrochlorothiazide. METHODS: To estimate
the economic impact a budget impact was developed using the Spanish national
healthcare system (NHS) perspective and a 3-year time horizon. The patient pop-
ulation was estimated based on disease prevalence, population growth and data on
the currently treated population with combinations of receptor blockers of the
antagonists of the angiotensin II (ARBII) with calcium channel blockers (CCB) alone
or together with diuretics (DIU) in fixed doses. Costs considered in this model
included drugs actually marketed or over the next three years consisting of Bal-
zak®, Balzak plus®, Capenon®, CapenonHCT®, Copalia®, CopaliaHCT®, Dafiro®,
DafiroHCT®, Exforge®, ExforgeHCT®, Imprida®, ImpridaHCT®, Twynsta®, Se-
vikar® and SevikarHCT® expressed in EUR 2010. Based on the annual drug costs
per patient and market shares for each treatment the economic burden before and
after the introduction of SevikarHCT® was estimated. A drop of 28% in drug prices
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was assumed when generic alternatives became available. RESULTS: The Spanish
population with arterial hypertension over 35 years treated with combinations of
ARBII and CCB with or without DIU was estimated at 990,000 patients in 2010,
expecting to rise to 1.17 million patients in 2013. Total treatment costs for hyper-
tension treatment over the next 3 years were estimated at €1.638 million before the
introduction of SevikarHCT® and at €1.649 million after introduction.
CONCLUSIONS:Although the introduction of SevikarHCT® adds incremental costs
for the Spanish NHS, a decrease in the overall economic burden with or without the
introduction of SevikarHCT® was observed from 2010. These budget savings can be
explained by the effect in price drop caused by the availability of generics.
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OBJECTIVES: To examine evidence on efficacy and safety of oral drugs for pulmo-
nary arterial hypertension (PAH). Analyze their utilization and their cost. To pro-
pose a treatment protocol based on efficacy, safety and efficiency. Calculate the
estimated budget impact after its implementation. METHODS: A search was con-
ducted in MEDLINE, EMBASE and Cochrane Database. Systematic reviews and
meta-analysis of bosentan, ambrisentan, sildenafil or tadalafil in PAH (functional
class II/III) were included. Their utilization was analyzed retrospectively in patients
with primary or associated with connective tissue diseases pulmonary hyperten-
sion that started treatment during 2008 to 2010. The annual cost per patient for
each alternative was calculated (standard dosage). A treatment protocol was de-
veloped, based on efficacy, safety, and efficiency. The incremental cost for each
drug, and the potential savings if all patients start their treatment with the most
cost-effective were calculated. RESULTS: No evidence was found to support the
superiority of any treatment over another, in terms of efficacy and/or safety. Sev-
enteen patients started treatment during the study period (47% bosentan, 41.2%
sildenafil, 11.8% ambrisentan). Estimated annual cost per patient: 30,987.07,
26,861.93, 7,807.74 and 6,865.65 €, for bosentan, ambrisentan, sildenafil and tada-
lafil, respectively. In absence of significant differences in efficacy or safety, the
treatment protocol was based on efficiency (sildenafil tadalafil ambrisentan
bosentan). Incremental cost (compared to sildenafil): 24,121.42, 19,996.28 and
€942.09 for bosentan, ambrisentan and tadalafil, respectively. Estimated potential
savings with implementation of protocol: 77,654.64 €/ year. CONCLUSIONS: No
evidence supports the superiority of any treatment over another, so they could be
considered equivalent therapeutic alternatives. Bosentan is most widely used drug
in naïve patients. The cost associated with bosentan/ambrisentan is markedly
greater to sildenafil/tadalafil. Establishing a protocol that prioritizes sildenafil/
tadalafil use would help to more efficient management of resources.
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OBJECTIVES: To ascertain the cost-utility of patient self-management (PSM) com-
pared to standard monitoring among long-term oral anticoagulation therapy pa-
tients in Austria. METHODS: A Markov model was used to combine international
effectiveness data and local cost and mortality data in a life-long simulation (closed
cohort with a mean baseline age of 67 years). Costs were calculated using informa-
tion on healthcare contacts from healthcare professionals and associated tariffs.
Costs for standard monitoring were based on monthly visits to primary/outpatient
settings and determination of PTZ levels. PSM costs included costs of the hand-
held device, materials, training and regular healthcare check-ups. Costs associated
with complications (thrombotic and haemorrhagic events) in primary-care, acute
care and rehabilitation settings were also considered, since complications occur at
different rates between monitoring strategies. Sensitivity analyses were
performed. RESULTS: PSM was associated with 15.9 life years or 10.7 QALYs com-
pared to 14.6 life years or 9.4 QALYs with standard monitoring. Costs per patient for
the entire period were €7,873 for PSM, €8,170 for monitoring by GPs, €8,354 for
monitoring by community-based consultants and € 8,810 for monitoring at a hos-
pital out-patient clinic. PSM was the dominant strategy for both the cost per life-
year gained and cost per QALY analysis. Although PSM led to higher initial costs
(between €908 and €916 per patient in the first year), follow-up costs were lower
(between €228 and €235 per patient per year thereafter) due to lower frequency of
health care visits. Standard monitoring was associated with monitoring costs of
between €273 and €391 per patient per year. CONCLUSIONS: Encouraging suitable
patients to self-manage leads to better health outcomes and lower costs. In Austria,
initial costs are compensated by lower complication rates and associated costs and
lower monitoring expenses. Cost-savings to the health sector could be accrued as
soon as 3 years after patients switch strategies.
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OBJECTIVES: PLATO was a multi centered, double blind, randomized study that
included 18,624 ACS patients from 43 countries, comparing ticagrelor  aspirin
versus clopidogrel aspirin. The PLATO demonstrated that ticagrelor was superior
on the primary composite endpoint: myocardial infarction, stroke, cardiovascular
death (HR 0.84, 95% CI: 0.77 to 0.92) without an increase in major bleedings com-
pared to clopidogrel, and whether the strategy of choice was invasive or conserva-
tive. The aim of this analysis is to estimate direct health care costs from a Spanish
health care perspective (excluding drug costs because ticagrelor price has not yet
been established). METHODS: Resource utilization was pre specified in the PLATO
trial and included hospitalization bed days, investigations, interventions and blood
products. Direct health care costs per patient at 12 months were estimated by
multiplying the resource use with Spanish unit costs derived from the Spanish
database e-salud, the GRDs of the Ministry of Health, published literature, and the
CMBD 2008. RESULTS: Ticagrelor resulted in numerically fewer bed days (mean
difference per patient 0.21, 95% CI -0.16 to 0.59), PCIs (mean difference per patient
0.01, 95% CI -0.01 to 0.03) and CABGs (mean difference per patient 0.01, 95% CI: 0.00
to 0.01). Ticagrelor is associated with €341 reduction per patient (95% CI: 31 to 652)
in healthcare costs at 12 months compared to clopidogrel. The reduction in health-
care costs was mainly due to fewer hospital days and cardiovascular interventions
in the ticagrelor group. The reduction in cost increased over the 12-month treat-
ment period consistent with the rate of clinical events over time in the PLATO
study. CONCLUSIONS: Treatment with ticagrelor is associated with cost savings in
patients with ACS at 12 months compared with clopidogrel (excluding drug costs)
from a Spanish health care perspective. However, the total cost savings will depend
on drug price, data not available yet.
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OBJECTIVES: To assess the clinical and economic burden of major bleeding in
abdominal surgery patients. METHODS: A retrospective study (January 1, 2005 to
December 31, 2007) was conducted using a medical claims database. Patients in-
cluded in the study were admitted to the hospital with abdominal surgery as their
primary procedure. Patients’ demographic, clinical and discharge statuses were
compared using Chi-square testing and standardized differences. Risk-adjusted
health care visits and costs were estimated using the General Linear Model (GLM).
Potential risk factors for venous thromboembolism (VTE) events were selected
using the Cox Proportional Hazard Regression Model. RESULTS: In patients identi-
fied with abdominal surgery (n49,355), 773 (1.57%) suffered major bleeding in the
6-month follow-up period. Compared with patients who did not suffer major bleed-
ing, patients who did were more likely to be older, have higher Charlson Comor-
bidity Index (CCI) scores and have other comorbid conditions such as cancer. The
percentage of patients who had baseline emergency room (ER) visits was also
higher in the major bleeding group. After risk-adjustment for pre-specified covari-
ates, inpatient ($21,573 vs. $10,954), outpatient ($12,891 vs. $7,852) and pharmacy
costs ($2,025 vs. $1,901) were higher for patients who suffered major bleeding. In
addition, patients with major bleeding events had higher readmission rates (0.11%
vs. 0.03%) during the follow-up period. CONCLUSIONS: Since the health care costs
of patients with major bleeding events were significantly higher than those of
patients without, it is important for individual hospitals to improve major bleeding
prophylaxis therapy.
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OBJECTIVES: To estimate clinical outcomes, health care utilization and cost bur-
den of patients who suffered a transient ischemic attack (TIA) during the 180 days
after a diagnosis of non-valvular atrial fibrillation (NVAF) and compare it with
patients who did not. METHODS: Based on 2005-2007 US insurance claim files,
patients aged 65 years and older who have had two or more primary diagnoses of
NVAF, occurring within 30 days of one another, were selected. The 180 days fol-
low-up event rates, health care facility use and costs for patients with and without
a TIA were compared. Risk adjustment was performed using the propensity score
matching (PSM) method with the ProbChoice™ algorithm. RESULTS: A total of
18,575 patients were identified with NVAF, of which 163 (0.88%) suffered a TIA
during the 180 days after the NVAF diagnosis. Patients were not significantly dif-
ferent in terms of gender, region, and baseline comorbid conditions. After PSM
risk-adjustment for pre-specified covariates, outpatient emergency room (ER) vis-
its (85.89% vs. 48.47% p0.0001), cardiovascular-related length of stay (6.59 days vs.
5.57 days, p0.0001) and ischemic stroke events (89.57 vs. 8 /100 person years,
p0.0001) were higher for patients who suffered a TIA compared to those who did
not. Although risk-adjusted outpatient office visit, international normalized ratio
(INR) testing, Coumadin outpatient visit, drug and other costs did not differ signif-
icantly between the two groups, patients who suffered a TIA had significantly
higher inpatient ($21,740 vs. $22,663, p0.0001) and total ($31,675 vs. $18,045,
p0.0001) expenditures. CONCLUSIONS: After adjusting for patient clinical and
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